Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer

The purpose of the present study was to identify a biomarker that can predict the response to preoperative chemoradiotherapy (PCRT) in esophageal cancer patients. Twenty-five serum samples collected from patents with esophageal cancer before PCRT (responder = 13, non-responder = 12) were analyzed by...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2019/10/01, Vol.42(10), pp.1766-1771
Main Authors: Nambu, Madoka, Masuda, Takeshi, Ito, Shingo, Kato, Ken, Kojima, Takashi, Daiko, Hiroyuki, Ito, Yoshinori, Honda, Kazufumi, Ohtsuki, Sumio
Format: Article
Language:English
Subjects:
Aged
biomarker
Biomarkers
Biomarkers, Tumor - blood
C-reactive protein
C-Reactive Protein - analysis
Cancer
Chemoradiotherapy
Chemotherapy
Esophageal cancer
Esophageal Neoplasms - blood
Esophageal Neoplasms - therapy
Esophagus
Female
Glycoproteins
Glycoproteins - blood
Health risk assessment
Humans
Interleukin 6
Leucine
leucine-rich alpha-2-glycoprotein 1
Male
Middle Aged
Proteomics
Radiation therapy
Receptors, Interleukin-6 - blood
Serum levels
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c703t-e14b0adc93ad2dc7351369d1eb12763093c9d745394ce06d43ab9026c0e57df23
cites cdi_FETCH-LOGICAL-c703t-e14b0adc93ad2dc7351369d1eb12763093c9d745394ce06d43ab9026c0e57df23
container_end_page 1771
container_issue 10
container_start_page 1766
container_title Biological & pharmaceutical bulletin
container_volume 42
creator Nambu, Madoka
Masuda, Takeshi
Ito, Shingo
Kato, Ken
Kojima, Takashi
Daiko, Hiroyuki
Ito, Yoshinori
Honda, Kazufumi
Ohtsuki, Sumio
description The purpose of the present study was to identify a biomarker that can predict the response to preoperative chemoradiotherapy (PCRT) in esophageal cancer patients. Twenty-five serum samples collected from patents with esophageal cancer before PCRT (responder = 13, non-responder = 12) were analyzed by quantitative proteomics, and 248 proteins were identified. Among them, the serum levels of leucine-rich alpha-2-glycoprotein 1 (LRG1) were significantly different (p 0.8) between responder and non-responder groups. The combination of LRG1 with C-reactive protein (CRP) and soluble interleukin-6 receptor (sIL-6R), which were previously reported as biomarkers predicting PCRT response, further improved the predictive performance, providing an AUC of greater than 0.9. The present results suggest that LRG1 and its combination with CRP and sIL-6R are promising biomarker candidates to predict response to PCRT in esophageal cancer patients.
doi_str_mv 10.1248/bpb.b19-00395
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2301445332</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2301445332</sourcerecordid><originalsourceid>FETCH-LOGICAL-c703t-e14b0adc93ad2dc7351369d1eb12763093c9d745394ce06d43ab9026c0e57df23</originalsourceid><addsrcrecordid>eNpdUU2P0zAUtBCILYUjV2SJCxcv_shHfVy6S1mpEqsFzpbjvFIXJw52gtR_wU_m9YMikcOL9DyeGc8Q8lrwayGLxftmaK4boRnnSpdPyEyoomalFOVTMuNaLFglysUVeZHzjnNec6mekyuFO1lV5Yz8XsPkfA_s0bstvQnD1jLJVmHv4pDiCL6nguL4Amnq6H2mlj7EnH0TgH7wsbPpByQ6RvqQoPVupI-Qh9hnOO_iAMmO_hfQ5Ra6mGzr47jF3bCnm5joXY4o-R1soEvbO0gvybONDRlenf9z8u3j3dflJ7b-vLpf3qyZq7kaGYii4bZ1WtlWtq5WpVCVbgU0QtaV4lo53dZFqXThgFdtoWyjuawch7JuN1LNybsTLz7z5wR5NJ3PDkKwPcQpG6m4KPC-OkDf_gfdxSn16A5RopBKadSbE3ZCuYQBJdiYIXnMZ28EN4eqDFZlsCpzrArxb86sU9NBe0H_7QYBqxOgOyRrQ-wDFvVP2-W68TFEI_mRtJAoxKU0oq4qHLVQaiHxQ6bbE9Muj5j1Rcqm0bsAR2OFPPjEeXF4OXZbmwz06g-PZ73m</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2314233909</pqid></control><display><type>article</type><title>Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer</title><source>Free Full-Text Journals in Chemistry</source><creator>Nambu, Madoka ; Masuda, Takeshi ; Ito, Shingo ; Kato, Ken ; Kojima, Takashi ; Daiko, Hiroyuki ; Ito, Yoshinori ; Honda, Kazufumi ; Ohtsuki, Sumio</creator><creatorcontrib>Nambu, Madoka ; Masuda, Takeshi ; Ito, Shingo ; Kato, Ken ; Kojima, Takashi ; Daiko, Hiroyuki ; Ito, Yoshinori ; Honda, Kazufumi ; Ohtsuki, Sumio ; School of Pharmacy ; National Cancer Center Research Institute ; National Cancer Center Hospital ; Showa University School of Medicine ; hDepartment of Biomarkers for Early Detection of Cancer ; Kumamoto University ; Japan Agency for Medical Research and Development ; dDepartment of Gastrointestinal Medical Oncology ; bFaculty of Life Sciences ; fDivision of Gastrointestinal Oncology ; gDepartment of Radiation Oncology ; cAMED-CREST ; aDepartment of Pharmaceutical Microbiology ; eDepartment of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East</creatorcontrib><description>The purpose of the present study was to identify a biomarker that can predict the response to preoperative chemoradiotherapy (PCRT) in esophageal cancer patients. Twenty-five serum samples collected from patents with esophageal cancer before PCRT (responder = 13, non-responder = 12) were analyzed by quantitative proteomics, and 248 proteins were identified. Among them, the serum levels of leucine-rich alpha-2-glycoprotein 1 (LRG1) were significantly different (p &lt; 0.01) and well discriminated (area under the curve (AUC) of the receiver operating characteristic (ROC) curve &gt;0.8) between responder and non-responder groups. The combination of LRG1 with C-reactive protein (CRP) and soluble interleukin-6 receptor (sIL-6R), which were previously reported as biomarkers predicting PCRT response, further improved the predictive performance, providing an AUC of greater than 0.9. The present results suggest that LRG1 and its combination with CRP and sIL-6R are promising biomarker candidates to predict response to PCRT in esophageal cancer patients.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b19-00395</identifier><identifier>PMID: 31582665</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Aged ; biomarker ; Biomarkers ; Biomarkers, Tumor - blood ; C-reactive protein ; C-Reactive Protein - analysis ; Cancer ; Chemoradiotherapy ; Chemotherapy ; Esophageal cancer ; Esophageal Neoplasms - blood ; Esophageal Neoplasms - therapy ; Esophagus ; Female ; Glycoproteins ; Glycoproteins - blood ; Health risk assessment ; Humans ; Interleukin 6 ; Leucine ; leucine-rich alpha-2-glycoprotein 1 ; Male ; Middle Aged ; Proteomics ; Radiation therapy ; Receptors, Interleukin-6 - blood ; Serum levels ; Treatment Outcome</subject><ispartof>Biological and Pharmaceutical Bulletin, 2019/10/01, Vol.42(10), pp.1766-1771</ispartof><rights>2019 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c703t-e14b0adc93ad2dc7351369d1eb12763093c9d745394ce06d43ab9026c0e57df23</citedby><cites>FETCH-LOGICAL-c703t-e14b0adc93ad2dc7351369d1eb12763093c9d745394ce06d43ab9026c0e57df23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31582665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nambu, Madoka</creatorcontrib><creatorcontrib>Masuda, Takeshi</creatorcontrib><creatorcontrib>Ito, Shingo</creatorcontrib><creatorcontrib>Kato, Ken</creatorcontrib><creatorcontrib>Kojima, Takashi</creatorcontrib><creatorcontrib>Daiko, Hiroyuki</creatorcontrib><creatorcontrib>Ito, Yoshinori</creatorcontrib><creatorcontrib>Honda, Kazufumi</creatorcontrib><creatorcontrib>Ohtsuki, Sumio</creatorcontrib><creatorcontrib>School of Pharmacy</creatorcontrib><creatorcontrib>National Cancer Center Research Institute</creatorcontrib><creatorcontrib>National Cancer Center Hospital</creatorcontrib><creatorcontrib>Showa University School of Medicine</creatorcontrib><creatorcontrib>hDepartment of Biomarkers for Early Detection of Cancer</creatorcontrib><creatorcontrib>Kumamoto University</creatorcontrib><creatorcontrib>Japan Agency for Medical Research and Development</creatorcontrib><creatorcontrib>dDepartment of Gastrointestinal Medical Oncology</creatorcontrib><creatorcontrib>bFaculty of Life Sciences</creatorcontrib><creatorcontrib>fDivision of Gastrointestinal Oncology</creatorcontrib><creatorcontrib>gDepartment of Radiation Oncology</creatorcontrib><creatorcontrib>cAMED-CREST</creatorcontrib><creatorcontrib>aDepartment of Pharmaceutical Microbiology</creatorcontrib><creatorcontrib>eDepartment of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East</creatorcontrib><title>Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>The purpose of the present study was to identify a biomarker that can predict the response to preoperative chemoradiotherapy (PCRT) in esophageal cancer patients. Twenty-five serum samples collected from patents with esophageal cancer before PCRT (responder = 13, non-responder = 12) were analyzed by quantitative proteomics, and 248 proteins were identified. Among them, the serum levels of leucine-rich alpha-2-glycoprotein 1 (LRG1) were significantly different (p &lt; 0.01) and well discriminated (area under the curve (AUC) of the receiver operating characteristic (ROC) curve &gt;0.8) between responder and non-responder groups. The combination of LRG1 with C-reactive protein (CRP) and soluble interleukin-6 receptor (sIL-6R), which were previously reported as biomarkers predicting PCRT response, further improved the predictive performance, providing an AUC of greater than 0.9. The present results suggest that LRG1 and its combination with CRP and sIL-6R are promising biomarker candidates to predict response to PCRT in esophageal cancer patients.</description><subject>Aged</subject><subject>biomarker</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - analysis</subject><subject>Cancer</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - blood</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophagus</subject><subject>Female</subject><subject>Glycoproteins</subject><subject>Glycoproteins - blood</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Interleukin 6</subject><subject>Leucine</subject><subject>leucine-rich alpha-2-glycoprotein 1</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Proteomics</subject><subject>Radiation therapy</subject><subject>Receptors, Interleukin-6 - blood</subject><subject>Serum levels</subject><subject>Treatment Outcome</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdUU2P0zAUtBCILYUjV2SJCxcv_shHfVy6S1mpEqsFzpbjvFIXJw52gtR_wU_m9YMikcOL9DyeGc8Q8lrwayGLxftmaK4boRnnSpdPyEyoomalFOVTMuNaLFglysUVeZHzjnNec6mekyuFO1lV5Yz8XsPkfA_s0bstvQnD1jLJVmHv4pDiCL6nguL4Amnq6H2mlj7EnH0TgH7wsbPpByQ6RvqQoPVupI-Qh9hnOO_iAMmO_hfQ5Ra6mGzr47jF3bCnm5joXY4o-R1soEvbO0gvybONDRlenf9z8u3j3dflJ7b-vLpf3qyZq7kaGYii4bZ1WtlWtq5WpVCVbgU0QtaV4lo53dZFqXThgFdtoWyjuawch7JuN1LNybsTLz7z5wR5NJ3PDkKwPcQpG6m4KPC-OkDf_gfdxSn16A5RopBKadSbE3ZCuYQBJdiYIXnMZ28EN4eqDFZlsCpzrArxb86sU9NBe0H_7QYBqxOgOyRrQ-wDFvVP2-W68TFEI_mRtJAoxKU0oq4qHLVQaiHxQ6bbE9Muj5j1Rcqm0bsAR2OFPPjEeXF4OXZbmwz06g-PZ73m</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Nambu, Madoka</creator><creator>Masuda, Takeshi</creator><creator>Ito, Shingo</creator><creator>Kato, Ken</creator><creator>Kojima, Takashi</creator><creator>Daiko, Hiroyuki</creator><creator>Ito, Yoshinori</creator><creator>Honda, Kazufumi</creator><creator>Ohtsuki, Sumio</creator><general>The Pharmaceutical Society of Japan</general><general>Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20191001</creationdate><title>Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer</title><author>Nambu, Madoka ; Masuda, Takeshi ; Ito, Shingo ; Kato, Ken ; Kojima, Takashi ; Daiko, Hiroyuki ; Ito, Yoshinori ; Honda, Kazufumi ; Ohtsuki, Sumio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c703t-e14b0adc93ad2dc7351369d1eb12763093c9d745394ce06d43ab9026c0e57df23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>biomarker</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - analysis</topic><topic>Cancer</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - blood</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophagus</topic><topic>Female</topic><topic>Glycoproteins</topic><topic>Glycoproteins - blood</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Interleukin 6</topic><topic>Leucine</topic><topic>leucine-rich alpha-2-glycoprotein 1</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Proteomics</topic><topic>Radiation therapy</topic><topic>Receptors, Interleukin-6 - blood</topic><topic>Serum levels</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nambu, Madoka</creatorcontrib><creatorcontrib>Masuda, Takeshi</creatorcontrib><creatorcontrib>Ito, Shingo</creatorcontrib><creatorcontrib>Kato, Ken</creatorcontrib><creatorcontrib>Kojima, Takashi</creatorcontrib><creatorcontrib>Daiko, Hiroyuki</creatorcontrib><creatorcontrib>Ito, Yoshinori</creatorcontrib><creatorcontrib>Honda, Kazufumi</creatorcontrib><creatorcontrib>Ohtsuki, Sumio</creatorcontrib><creatorcontrib>School of Pharmacy</creatorcontrib><creatorcontrib>National Cancer Center Research Institute</creatorcontrib><creatorcontrib>National Cancer Center Hospital</creatorcontrib><creatorcontrib>Showa University School of Medicine</creatorcontrib><creatorcontrib>hDepartment of Biomarkers for Early Detection of Cancer</creatorcontrib><creatorcontrib>Kumamoto University</creatorcontrib><creatorcontrib>Japan Agency for Medical Research and Development</creatorcontrib><creatorcontrib>dDepartment of Gastrointestinal Medical Oncology</creatorcontrib><creatorcontrib>bFaculty of Life Sciences</creatorcontrib><creatorcontrib>fDivision of Gastrointestinal Oncology</creatorcontrib><creatorcontrib>gDepartment of Radiation Oncology</creatorcontrib><creatorcontrib>cAMED-CREST</creatorcontrib><creatorcontrib>aDepartment of Pharmaceutical Microbiology</creatorcontrib><creatorcontrib>eDepartment of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nambu, Madoka</au><au>Masuda, Takeshi</au><au>Ito, Shingo</au><au>Kato, Ken</au><au>Kojima, Takashi</au><au>Daiko, Hiroyuki</au><au>Ito, Yoshinori</au><au>Honda, Kazufumi</au><au>Ohtsuki, Sumio</au><aucorp>School of Pharmacy</aucorp><aucorp>National Cancer Center Research Institute</aucorp><aucorp>National Cancer Center Hospital</aucorp><aucorp>Showa University School of Medicine</aucorp><aucorp>hDepartment of Biomarkers for Early Detection of Cancer</aucorp><aucorp>Kumamoto University</aucorp><aucorp>Japan Agency for Medical Research and Development</aucorp><aucorp>dDepartment of Gastrointestinal Medical Oncology</aucorp><aucorp>bFaculty of Life Sciences</aucorp><aucorp>fDivision of Gastrointestinal Oncology</aucorp><aucorp>gDepartment of Radiation Oncology</aucorp><aucorp>cAMED-CREST</aucorp><aucorp>aDepartment of Pharmaceutical Microbiology</aucorp><aucorp>eDepartment of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>42</volume><issue>10</issue><spage>1766</spage><epage>1771</epage><pages>1766-1771</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>The purpose of the present study was to identify a biomarker that can predict the response to preoperative chemoradiotherapy (PCRT) in esophageal cancer patients. Twenty-five serum samples collected from patents with esophageal cancer before PCRT (responder = 13, non-responder = 12) were analyzed by quantitative proteomics, and 248 proteins were identified. Among them, the serum levels of leucine-rich alpha-2-glycoprotein 1 (LRG1) were significantly different (p &lt; 0.01) and well discriminated (area under the curve (AUC) of the receiver operating characteristic (ROC) curve &gt;0.8) between responder and non-responder groups. The combination of LRG1 with C-reactive protein (CRP) and soluble interleukin-6 receptor (sIL-6R), which were previously reported as biomarkers predicting PCRT response, further improved the predictive performance, providing an AUC of greater than 0.9. The present results suggest that LRG1 and its combination with CRP and sIL-6R are promising biomarker candidates to predict response to PCRT in esophageal cancer patients.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>31582665</pmid><doi>10.1248/bpb.b19-00395</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2019/10/01, Vol.42(10), pp.1766-1771
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_2301445332
source Free Full-Text Journals in Chemistry
subjects Aged
biomarker
Biomarkers
Biomarkers, Tumor - blood
C-reactive protein
C-Reactive Protein - analysis
Cancer
Chemoradiotherapy
Chemotherapy
Esophageal cancer
Esophageal Neoplasms - blood
Esophageal Neoplasms - therapy
Esophagus
Female
Glycoproteins
Glycoproteins - blood
Health risk assessment
Humans
Interleukin 6
Leucine
leucine-rich alpha-2-glycoprotein 1
Male
Middle Aged
Proteomics
Radiation therapy
Receptors, Interleukin-6 - blood
Serum levels
Treatment Outcome
title Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A23%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leucine-Rich%20Alpha-2-Glycoprotein%201%20in%20Serum%20Is%20a%20Possible%20Biomarker%20to%20Predict%20Response%20to%20Preoperative%20Chemoradiotherapy%20for%20Esophageal%20Cancer&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Nambu,%20Madoka&rft.aucorp=School%20of%20Pharmacy&rft.date=2019-10-01&rft.volume=42&rft.issue=10&rft.spage=1766&rft.epage=1771&rft.pages=1766-1771&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b19-00395&rft_dat=%3Cproquest_cross%3E2301445332%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c703t-e14b0adc93ad2dc7351369d1eb12763093c9d745394ce06d43ab9026c0e57df23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2314233909&rft_id=info:pmid/31582665&rfr_iscdi=true